Phase 2 Breast Cancer Trial, Recruiting NCT07657130 Sponsor: Liaoning Cancer Hospital & Institute Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT07657130
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a woman between 18 and 75 years old
  • You have been diagnosed with advanced breast cancer that has been confirmed by laboratory testing to be HER2-negative (a specific type based on test results)
  • Your cancer got worse after receiving a first standard chemotherapy treatment for advanced or spread cancer (and if your cancer is hormone receptor-positive, you must also have received at least one hormone-blocking therapy)
  • You are fairly active and able to carry out daily activities without much difficulty, as measured by a standard health scale (confirm with trial site)
  • Doctors estimate you have a life expectancy of at least 12 weeks
  • Your bone marrow is working well enough, shown by blood tests checking your white blood cells, platelets, and red blood cells meeting certain minimum levels (confirm with trial site)
  • Your liver and kidneys are working well enough, based on blood and urine tests meeting certain minimum levels (confirm with trial site)
  • You are willing and able to sign a consent form agreeing to take part in the study

Who may not be able to join:

  • You have previously been treated with a type of cancer drug called an ADC (antibody-drug conjugate) after your cancer came back or spread
  • You are currently pregnant or breastfeeding
  • Your cancer cannot be measured or tracked using standard medical imaging criteria (confirm with trial site)
  • You have cancer that has spread to the brain or surrounding tissue and is causing symptoms that are not well controlled by treatment
  • You have had another type of cancer in the past 5 years, with some exceptions for certain minor or well-treated skin or cervical conditions (confirm with trial site)
  • You have a mental health condition or other issue that may make it difficult to follow the study requirements
  • You have a serious ongoing health condition affecting your heart, lungs, metabolism, or blood vessels that is not well controlled
  • You are currently taking part in another clinical trial or took an experimental drug within the last 30 days before joining
  • You have a known allergy to any of the drugs or ingredients used in this study
  • Your doctor feels there is any other reason that makes it unsafe or unsuitable for you to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Tao Sun, Liaoning Cancer Hospital & Institute

Phone: 0086-19800367870

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Liaoning Cancer Hospital & Institute
Registry
ClinicalTrials.gov
Start date
1 July 2025
Est. completion
30 June 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression-free survival 2 (PFS2)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov